Search Within

Leonard B Saltz

Formats
  1. Journal Article (484)
  2. Meeting Abstract (254)
  3. Book Section (24)
  4. Guidelines (12)
  5. Editorial (8)
  6. Correspondence (5)
  7. Review (4)
  8. Book Whole (2)
  9. Conference Paper (2)
  10. Research Letter (1)
Groups
  1. Department of Medicine (796)
  2. Gastrointestinal Oncology Service (796)
  3. Solid Tumor Oncology Division (796)
  4. Center for Pancreatic Cancer Research (309)
  5. Surgery (236)
  6. Survivorship Research (232)

More Groups

People
  1. Martin Weiser (133)
  2. Andrea Cercek Hanjis (127)
  3. Philip Paty (122)
  4. Jinru Shia (101)
  5. Nancy Kemeny (98)
  6. Jose Guillem (89)

More People

Years
  1. 2025 (16)
  2. 2024 (21)
  3. 2023 (24)
  4. 2022 (22)
  5. 2021 (18)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (271)
  2. Journal of the National Comprehensive Cancer Network (42)
  3. Annals of Oncology (36)
  4. Cancer (31)
  5. Clinical Cancer Research (27)
  6. Annals of Surgical Oncology (26)

More Publications

Publishers
  1. American Society of Clinical Oncology (287)
  2. Oxford University Press (82)
  3. Elsevier Inc. (73)
  4. Springer (49)
  5. Harborside Press (42)
  6. American Association for Cancer Research (41)

More Publishers

Results (796)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer
    Meeting Abstract

    Saltz, L.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.; Cassidy, J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803
    Meeting Abstract

    Meyerhardt, J. A.; Niedzwiecki, D.; Hollis, D.; Saltz, L.; Willett, W.; Mayer, R. J.; Fuchs, C. S.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors
    Meeting Abstract

    Love, N.; Bylund, C.; Meropol, N. J.; Marshall, J. L.; Curley, S. A.; Ellis, L. M.; Grothey, A.; Lenz, H. J.; Saltz, L. B.; Elder, M. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Huitzil, F. D.; Capanu, M.; Jacobs, G.; Smith, W.; O'Reilly, E.; Shah, M.; Schwartz, G. K.; Saltz, L. B.; Kelsen, D. P.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer
    Meeting Abstract

    Garrison, L.; Cassidy, J.; Saleh, M.; Lee, F.; Mena, R.; Fuloria, J.; Chang, V.; Ervin, T.; Stella, P.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies
    Meeting Abstract

    Giantonio, B. J.; Meropol, N. J.; Catalano, P. J.; Ng, V.; Oliver, R.; Sirzen, F.; Leonard, S.; Cassidy, J.; Benson, A. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)
    Meeting Abstract

    Goldberg, R. M.; Köhne, C. H.; Seymour, M. T.; de Gramont, A.; Porschen, R.; Saltz, L.; Rougier, P.; Tournigand, C.; Grothey, A.; Sargent, D. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
    Meeting Abstract

    Folprecht, G.; Seymour, M. T.; Saltz, L.; Douillard, J. Y.; Stephens, R. J.; Van Cutsem, E.; Rougier, P.; Maughan, T. S.; Köhne, C. H.; Ironotecan Meta-analysis Group
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
    Meeting Abstract

    Chung, K. Y.; Gore, I.; Fong, L.; Venook, A.; Dorazio, P.; Healey, D.; Pavlov, D.; Saltz, L. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save